Introduction and hypothesis We compared treatment success and adverse events between women undergoing open abdominal sacrocolpopexy (ASC) vs vaginal repair (VAR) using data from women enrolled in one of three multicenter trials. We hypothesized that ASC would result in better outcomes than VAR. Methods Participants underwent apical repair of stage 2-4 prolapse. Vaginal repair included uterosacral, sacrospinous, and iliococcygeal suspensions; sacrocolpopexies were via laparotomy. Success was defined as no bothersome bulge symptoms, no prolapse beyond the hymen, and no retreatment up to 24 months. Adverse events were collected at multiple time points. Outcomes were analyzed using longitudinal mixed-effects models to obtain valid outcome estimates at specific visit times, accounting for data missing at random. Comparisons were controlled for center, age, body mass index (BMI), initial Pelvic Organ Prolapse Quantification (POP-Q) stage, baseline scores, prior prolapse repair, and concurrent repairs. Results Of women who met inclusion criteria (1022 of 1159 eligibile), 701 underwent vaginal repair. The ASC group (n = 321) was older, more likely white, had prior prolapse repairs, and stage 4 prolapse (all p < 0.05). While POP-Q measurements and symptoms improved in both groups, treatment success was higher in the ASC group [odds ratio (OR) 6.00, 95% confidence interval (CI) 3.45-10.44). The groups did not differ significantly in most questionnaire responses at 12 months and overall improvement in bowel and bladder function. By 24 months, fewer patients had undergone retreatment (2% ASC vs 5% VAR); serious adverse events did not differ significantly through 6 weeks (13% vs 5%, OR 2.0, 95% CI 0.9-4.7), and 12 months (26% vs 13%, OR 1.6, 95% CI 0.9-2.9), respectively. Conclusions Open sacrocolpopexy resulted in more successful prolapse treatment at 2 years.
Introduction
Surgeons who practice evidence-based reconstructive pelvic surgery seek the highest level of evidence for their surgical recommendations. However, a significant knowledge gap exists for pelvic reconstructive surgeons who counsel the many women planning surgery for prolapse repair. Ideally, welltrained surgeons should be able to counsel and offer patients a variety of approaches and discuss the balance of benefits and risks of techniques based on high-quality evidence, including counseling regarding the impact of repair on bowel, bladder, and sexual function. Although previous randomized trials have compared outcomes of open abdominal sacrocolpopexy (ASC) vs vaginal prolapse repair (VAR), these trials have drawbacks, including small sample sizes, different types of procedures for both the abdominal and vaginal approaches, and lack of standardized outcome measures, particularly for bowel, bladder, and sexual function [1] [2] [3] [4] . While data from these trials do show more durability in the short term for ASC, it is unclear whether functional outcomes are similar between the two approaches.
We compared success and adverse events (AEs) between ASC and VAR using data from three multicenter randomized trials that used standardized outcomes of pelvic reconstructive surgery for stage 2-4 pelvic organ prolapse (POP). In our study, pre-existing data from National Institute of Child Health and Human Development (NICHD) trials included validated measurement of both anatomic, symptom, and quality of life (QoL) data, as well as detailed descriptions of AEs. We hypothesized that ASC would result in better anatomic and QoL outcomes than VAR. Our ultimate goal is to inform design, conduct, and analysis of future randomized trials and improve evidence regarding surgical approach for women with stage 2-4 POP.
Materials and methods
We present a retrospective study of participants enrolled in one of three NICHD Pelvic Floor Disorders Network trials conducted in 17 centers throughout the United States; all women underwent surgical correction of stage 2-4 POP with an apical suspension technique. The trials in this study are the Colpopexy and Urinary Reduction Efforts (CARE) [5] , Outcomes following Vaginal Prolapse Repair and Midurethral Sling (OPUS) [6] , and the Operations and Pelvic Muscle Training in the Management of Apical Support Loss (OPTIMAL) trials [7] . Designs and results of these trials have been previously published. Briefly, in the CARE trial, women with stress urinary incontinence (SUI) underwent abdominal ASC surgery for POP and were randomized to prophylactic Burch cystourethropexy continence surgery vs no Burch to evaluate the effectiveness of concomitant prophylactic continence surgery at the time of open abdominal surgery for POP [5] . Participants in the OPUS trial underwent vaginal prolapse surgery with a retropubic midurethral sling compared with a sham procedure to evaluate the efficacy of concomitant prophylactic continence surgery at the time of vaginal surgery for POP [7] . In both CARE and OPUS trials, women were not randomized to different types of repair. However, the OPTIMAL trial was designed with the primary aim to compare two native-tissue vaginal approaches apical POP repair, and women were randomized to sacrospinous or uterosacral colpopexy [6] . The CARE and OPTIMAL trials were designed to follow patients for 2 years after surgery and the OPUS trial for 1 year.
For this study, we defined two separate groups: ASC and VAR. We excluded women who underwent colpocleisis or mesh procedures for prolapse and women whose only apical procedure was ligation of the peritoneal sac or trachelectomy. For the ASC group, we included women in the CARE trial. For the VAR group, we included women in the OPUS and OPTIMAL trials who underwent either iliococcygeal, McCall's culdoplasty, sacrospinous, or uterosacral colpopexy. We combined anterior colporrhaphy with abdominal paravaginal repairs to an anterior repair variable; all colporrhaphies were performed vaginally, and all paravaginal repairs were performed abdominally. We also combined posterior repair and perineorrhaphy into a posterior repair variable, as surgeons vary widely in their definition of how they perform these two repairs and there is likely crossover between techniques [8] .
Our primary outcome was success after POP surgery defined as the absence of bothersome bulge symptoms, no prolapse beyond the hymen, and no subsequent retreatment of prolapse up to 24 months. Bothersome bulge was measured by the Pelvic Organ Prolapse Distress Inventory (POPDI) [9] Question 5 (Do you usually have a bulge or something falling out that you can see or feel in the vaginal area?). Patients responded either "Not at all" or "Yes." If yes, they were asked "How much does it bother you?". No prolapse beyond the hymen was measured on the Pelvic Organ Prolapse Quantification (POP-Q) examination (i.e., ≤0 on points Ba, C, and Bp) [10, 11] . Participants failing any one of the three criteria were considered surgical failures; women whose status could not be determined due to missing data for the three criteria were excluded from this analysis. Our secondary outcomes were symptom and QoL measures. POP-Q, Pelvic Floor Distress Inventory-20 (PFDI-20), Pelvic Floor Impact Questionnaires-7 (PFIQ-7) and Pelvic Organ Prolapse/ Urinary Incontinence Sexual Questionnaire-12 (PISQ-12) measures were administered at baseline and each follow-up visit [9, 12, 13] . The PFDI-20 comprised the Urinary Distress Inventory (UDI), Colorectal Anal Distress Inventory (CRADI), and POPDI subscales. The PFIQ-7 comprised the Urinary Impact Questionnaire (UIQ), the Colorectal Anal Impact Questionnaire (CRAIQ), and Pelvic Organ Prolapse Impact Questionnaire (POPIQ) subscales. Higher scores on the PFDI-20 and PFIQ-7 indicate greater bother and negative impact on QoL, respectively, and higher PISQ-12 scores indicate better sexual function.
Complications and serious AEs (SAE) were recorded on standardized forms for all trials. Perioperative complications were recorded up to 6 weeks postoperatively and included blood transfusions, deep vein thrombosis, pulmonary embolus, and injuries to ureters, bladder, urethra, bowel, vascular system, and nerves. Only SAEs were recorded consistently across all studies after the perioperative period, from 6 weeks to 1-2 years postoperatively. These events were categorized using the Dindo complication scale [14] .
Demographics and baseline characteristics were compared between treatment groups using analysis of variance (ANOVA) for continuous normally distributed measures, Kruskal-Wallis tests for non-normally distributed scale measures, mean score tests using standardized rank scores for ordinal categorical measures, and chi-square tests for general association for categorical measures. By design, timing of follow-up visits varied by study. Success and QoL outcomes measured at multiple visits were analyzed using longitudinal mixed-effects models (for continuous measures) or generalized linear models with empirical variance estimates (for binary measures) to obtain valid outcome estimates at specific visit times, accounting for data missing at random or missing completely at random due to events that occurred rarely. Additionally, models for PFDI-20, PFIQ-7, and PISQ-12 scores also controlled for the corresponding baseline score. Hypotheses for these outcomes were tested using contrast statements for assessing whether differences existed between the two groups across study follow-up as well as at individual visit times. SAEs were graded by the Dindo score and compared between groups using analysis of covariance (ANCOVA) techniques for continuous measures, covariate adjusted logistic models for categorical measures, and covariate adjusted mean score tests using modified ridit scores for ordinal categorical measures. Due to low rates of occurrence, the percent of women experiencing specific complications during the perioperative and 6-week postoperative period was compared between treatment groups using Fisher's exact test without adjustments.
Results
For these analyses, 1022 of 1159 eligible women from the parent studies met inclusion criteria. Fig. 1 outlines the contribution to the study population from each of the parent studies. On average, participants in the ASC group were older, had lower BMI, and were more likely to be white, postmenopausal, and privately insured. Of the 701 patients who had vaginal surgery, 296 (42%) had outpatient surgery, 402 (57%) had in-patient surgery, and three (1%) had missing information. Of the 402 in-patients, mean [standard deviation (SD)] length of stay was 1.4 (0.7) days (median 1 day). All 321 patients who had ASC surgery were inpatients; they had a mean (SD) length of stay of 2.8 (1.1) days (median 3 days). They were more likely to have undergone prior incontinence or prolapse procedures. (Table 1 ) Importantly, they did not differ in rates of sexual activity, mean number of vaginal births, smoking history, or the 36-Item Short-Form Health Survey (SF-36) physical component scores. Women in the ASC group had more severe prolapse as measured by the POP-Q, and reported less bother preoperatively from urinary and colorectal symptoms on the PFDI-20 and less QoL impact on the PFIQ-7. Interestingly, despite differences in severity of prolapse as measured by the POP-Q, baseline POPDI subscale scores were not different between groups. (Table 2 ) As is common with pelvic reconstructive surgery, women underwent a variety of concomitant procedures. (Table 3 ). For our composite definition of success, outcomes were better in the ASC group at every time point. Overall treatment success was higher in the ASC group [odds ratio (OR) 6.00, 95% confidence interval (CI) 3.45-10.44]. (Table 4) Likewise, POP-Q measurement of points Ba and C were better in the ASC group at all time points. Outcomes in the posterior compartment were similar between groups at all time points. Retreatment of prolapse was low in both groups, with only 2% of the ASC and 5% of the VAR group reporting retreatment prior to 24 months.
Bowel and bladder function as measured by the PFDI-20 and PFIQ-7 improved in both groups. (Table 5 ) Overall, adjusted results showed no difference in improvement between groups, including in UDI, POPDI, CRADI, UIQ, POPIQ, and CRAIQ subscale scores. POPDI slightly greater improvement at 24 months in the ASC group, but no difference was seen before this time point. PISQ-12 scores showed no difference in improvement between groups. Table 6 displays AEs. Although SAEs were more common in the ASC group at 6 weeks and 1 year, after statistically adjusting for center, apical procedure type, and occurrence of posterior or anterior procedure, the groups were similar. Visceral injury, transfusion, pulmonary embolus, and deep vein thrombosis were rare. Mesh erosion rates 
Discussion
Two years following surgery, open ASC is associated with better composite outcome success rates and no significant differences in AEs than VAR for prolapse. Patient QoL and symptom bother outcomes were similar, and low reoperation rates were observed for both groups. Published symptom and anatomic outcomes, complications, and reoperation rates for these procedures have significant limitations. A meta-analysis of comparative studies reported improved anatomic outcomes with colpopexy over native tissue repair with an increased risk of AEs; however, there was insufficient evidence to make any statements regarding the impact on bowel or bladder function [15] . Three published randomized trials comparing open ASC with sacrospinous ligament fixation (SSLF) are summarized in a second meta-analysis [1] [2] [3] [4] , which supported superior anatomic outcomes for open ASC but with longer operating times and recovery. Because of the transition to minimally invasive routes for ASC, the authors of the meta-analysis concluded that further evidence comparing minimally invasive approaches to ASC and VAR with and without mesh are needed [1] . Thus, existing randomized data directly comparing ASC and VAR prolapse repairs do not allow an evidence-based decision regarding the best route of apical prolapse surgery for each patient with prolapse [1] . In our retrospective study, combining data from three NICHD trials allowed us to evaluate a large number of women with validated anatomical, QoL, bowel, bladder, and sexual function outcomes as well as to evaluate AEs throughout SAEs did not differ between groups. Individual events commonly associated with surgery, including thrombosis, pulmonary emboli, and ureteral injury, were very low, and we likely did not have enough power to detect differences between groups. Although perioperative complications after sacrospinous ligament fixation are uncommon, the consequences for individual patients can be significant. Buttock pain occurs in 3% but is usually self-limited, whereas sacral/ pudendal neurovascular injury can result in transfusion in 2% and life-threatening hemorrhage in 0.2% [16] . In our study, transfusion was rare and occurred in both cohorts. Ureteral kinking or injury is commonly associated with transvaginal uterosacral colpopexy; however, most of these are identified intraoperatively, and only 0.6% of patients require interval ureteral reimplantation [17] . Immediate perioperative complications of open ASC include wound complications in 4.6%, hemorrhage/transfusion in 4.4%, and visceral injury in 1-3.1%. We found more ureteral kinking in our VAR group, but long-term sequelae was low. Rates of other visceral injuries were very low in both groups. Erosion of colpopexy material is one of the main concerns with ASC, occurring in 3.4% of 2178 cases 3 years after surgery, regardless of type of material used, and requiring reoperation in 3% [18] . In the CARE trial, from which our ASC cases were gathered, mesh erosion was thought to occur only in the first few years after surgery. However, longer follow-up in this cohort has documented a 10.5% rate of mesh erosion by 7 years postoperatively [19] . The CARE trial allowed multiple forms of synthetic mesh, some of which are no longer commonly used. In addition, the anatomical failure rate in the long-term CARE follow-up was much higher than anticipated and ranged from 24 to 48%, depending on the definition used. Our retrospective comparison benefited from combined data from three large multicenter randomized trials with well-characterized participants, using the same validated pelvic floor symptom distress and impact measures and systematic collection of AEs. It allowed a robust comparison of prospectively collected 1-and 2-year outcomes in women undergoing vaginal apical reconstructive surgery to those undergoing an open abdominal approach. These data should be considered in light of their limitations. A comparative retrospective study has inherent biases regarding patient allocation. Patient characteristics were significantly different between groups, with the ASC group being older, having greater prolapse, more previous surgeries for prolapse repair, and less bothersome urinary and bowel symptoms at baseline. Although we detected better outcomes in the ASC group, the baseline differences between groups may have diminished the differences observed. Despite excellent patient follow-up and standardized data collection, one of the two vaginal trials only collected 12-month outcomes. Outcomes >12 months were inferred using longitudinal mixed-effects models (for continuous measures) or generalized linear models with empirical variance estimates (for binary measures) to obtain valid outcome estimates at specific visit times, accounting for data missing at random or missing completely at random due to the varied planned visits. These assumptions may not be correct and may have favored the VAR group, underestimating the observed better outcomes in the ASC group.
Surgical techniques have evolved with time. The three studies in this analysis did not include transvaginal mesh or minimally invasive colpopexy procedures, and there were no data on why patients were offered a vaginal or abdominal approach. Therefore, we are limited in our ability to comment on the role of these procedures in POP repair. A higher number of patients had undergone prior prolapse repairs, and a history of prior repair may have important implications on success of the current attempt at repair. Surgical technique varies with individual surgeons, and technique may account for some differences. There may have been other differences we did not measure or control for that influenced our findings.
In conclusion, in a careful examination of pre-existing data sets from three large trials of prolapse repair, ASC was more likely to result in treatment success and was not significantly associated with greater rates of serious AEs compared with VAR. Bowel, bladder, and prolapse functional results improved in both groups similarly. A randomized trial of vaginal and minimally invasive abdominal surgical approaches in women with apical prolapse with longer-term outcomes, accompanied by cost effectiveness and robust AE analyses, would more fully inform surgical practice and counseling.
